Device Trial Radar · NCT05108883
Risk Stratification Using Midregional Proadrenomedullin in the ED
Last checked: Nov 19, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
463
Actual
Start
Oct 14, 2021
Primary completion
Nov 7, 2023
Study completion Nov 7, 2023
Sponsor
- Lead sponsor
- Brahms AGNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 5, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Emergency departments (ED) are becoming increasingly over-crowded, with patients facing prolonged waiting times. Therefore, a safe and rapid assessment that identifies patients with low severity that could be treated as outpatients is essential for improving the workflow within the ED. The rationale of this IDEAL+ study is to safely decrease the number of hospital admissions through identification of low risk patients with the biomarker MR-proADM. This will has already been tested in the IDEAL - pilot study and results should be confirmed with this IDEAL+ study.
Conditions
- Patients Presenting With Suspicion of Infection to the ED
Interventions
MR-proADM KRYPTORDevice
MR-proADM ≤ 0.87 nmol/L together with routine clinical evaluation identifies patients with low disease severity who do not need to be hospitalized
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of out-patients re-presenting to the EDTime frame: 5 days
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
Hôpital Pitié-Salpêtrière, AP-HP.Sorbonne Université
Paris, France
Policlinico Tor Vergata
Roma, Italy
Hospital Santa Maria della Misericordia
Udine, Italy
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.